Tempo Therapeutics secured $12M in Series A financing led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. to advance its synthetic tissue scaffold candidates into clinical trials.

Mar 19, 2024•over 1 year ago

Amount Raised

$12 Million

Round Type

series a

San DiegoBiotechnology

Investors

Johnson & Johnson Innovation – Jjdc, Inc.Galaxy Sirius Partners

Description

Tempo Therapeutics announced the successful completion of its $12 million Series A equity financing round led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc. The funding will propel Tempo forward as it advances its revolutionary Microporous-Annealed-Particle (MAP) technology platform and takes its synthetic tissue scaffold candidates into clinical trials.

Company Information

Company

Tempo Therapeutics

Location

3030 BUNKER HILL STREET

San Diego, California, United States

About

Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology. Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends